Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

HCV-viremic kidney transplantations had similar outcomes to non-HCV kidneys independent of recipient serostatus

Key clinical point: Heptatis C virus (HCV)–viremic kidneys functioned similarly in recipients who were seropositive or seronegative for HCV.

Major finding: The 12-month estimated glomerular filtration rate was similar between the two groups (65.4 vs. 71.1 mL/min per 1.73 m2).

Study details: Registry study including 269 HCV-viremic kidney transplantations.

Disclosures: This work was supported in part by the Health Resources and Services Administration of the U.S. Department of Health & Human Services. The various authors reported grant funding and advisory board participation with a number of pharmaceutical companies.


Potluri VS et al. J Am Soc Nephrol. 2019;30:1939-51.